Search

Rheumatic heart disease across the Western Pacific: not just a Pacific Island problem

We aimed to review RHD burden in Western Pacific Region outside Oceania to identify countries with high RHD burden

Improving cardiovascular outcomes among Aboriginal Australians: Lessons from research for primary care

Primary care practitioners have an important role in improving Aboriginal cardiovascular care outcomes

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015

Globally, life expectancy from birth increased from 61·7 years in 1980 to 71·8 years in 2015

Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015

Total global disability-adjusted life-years remained largely unchanged from 1990 to 2015

Acute Rheumatic Fever Diagnosis Collaborative Network (ARC)

ARC is a global network of collaborators committed to reducing the burden of RHD in our lifetime.

Australian Strep A Vaccine Initiative (ASAVI)

The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.

BPG Formulation Preferences Study: Exploring patient, family and clinician reformulations preferences for BPG

The key objective of this study is to collect data about patient and clinician preferences about reformulations.

Burden of rheumatic heart disease (RHD) and impact of prevention strategies: comprehensive evidence to drive the RHD Endgame

This project will use a multi-jurisdictional linked RHD dataset to establish a baseline burden of RHD in Australia to allow for monitoring the impact of burden over time, and to form the basis of clearly defined targets for the END RHD CRE Endgame Strategy.

Defining target penicillin concentrations for subsequent studies of a reformulated long-acting benzathine penicillin prototype

Aims: To determine the minimum inhibitory concentrations of penicillin G against a representative collection of Strep A strains; and to evaluate the impact of penicillin G concentration and size of bacterial inoculum on the prophylactic effect for Strep A strains

Development of a longer acting formulation of Penicillin G for the treatment and prevention of acute rheumatic fever and rheumatic heart disease

This project aims to develop a longer acting formulation of penicillin, such that frequency of the injection can be increased up to 3-6 months.